{"id":"NCT00501293","sponsor":"Noven Therapeutics","briefTitle":"Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD","officialTitle":"A Phase IIIb, Long-Term, Open-Label, Multi-Center, Extension Study Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2009-02","completion":"2009-02","firstPosted":"2007-07-16","resultsPosted":"2010-01-15","lastUpdate":"2017-04-26"},"enrollment":163,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["ADHD"],"interventions":[{"type":"DRUG","name":"Methylphenidate Transdermal System","otherNames":["DAYTRANA"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"To evaluate the long-term, safety of Methylphenidate Transdermal System (MTS) in aged 13-17 years diagnosed withADHD","primaryOutcome":{"measure":"Systolic Blood Pressure","timeFrame":"Baseline and 6 months","effectByArm":[{"arm":"Antecedent Methylphenidate Transdermal System (MTS)","deltaMin":113.4,"sd":9.59},{"arm":"Antecedent Placebo","deltaMin":113,"sd":11.2}],"pValues":[]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":4},"locations":{"siteCount":32,"countries":["United States"]},"refs":{"pmids":["20973707"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":109},"commonTop":["Decreased appetite","Headache","Upper respiratory tract infection","Nasopharyngitis","Irritability"]}}